154 related articles for article (PubMed ID: 2967824)
1. Matrix plasminogen activator inhibitor. Modulation of the extracellular proteolytic environment.
Knudsen BS; Nachman RL
J Biol Chem; 1988 Jul; 263(19):9476-81. PubMed ID: 2967824
[TBL] [Abstract][Full Text] [Related]
2. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells.
Mimuro J; Loskutoff DJ
J Biol Chem; 1989 Mar; 264(9):5058-63. PubMed ID: 2494180
[TBL] [Abstract][Full Text] [Related]
3. Interaction of wild-type and catalytically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers.
Ramakrishnan V; Sinicropi DV; Dere R; Darbonne WC; Bechtol KB; Baker JB
J Biol Chem; 1990 Feb; 265(5):2755-62. PubMed ID: 2105933
[TBL] [Abstract][Full Text] [Related]
4. Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha.
de Bart AC; Quax PH; Löwik CW; Verheijen JH
J Bone Miner Res; 1995 Sep; 10(9):1374-84. PubMed ID: 7502710
[TBL] [Abstract][Full Text] [Related]
5. Interactions between tissue-type plasminogen activator and extracellular matrix-associated plasminogen activator inhibitor type 1 in the human hepatoma cell line HepG2.
Owensby DA; Morton PA; Schwartz AL
J Biol Chem; 1989 Oct; 264(30):18180-7. PubMed ID: 2553701
[TBL] [Abstract][Full Text] [Related]
6. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin.
Seiffert D; Mimuro J; Schleef RR; Loskutoff DJ
Cell Differ Dev; 1990 Dec; 32(3):287-92. PubMed ID: 1711915
[TBL] [Abstract][Full Text] [Related]
7. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.
Kost C; Stüber W; Ehrlich HJ; Pannekoek H; Preissner KT
J Biol Chem; 1992 Jun; 267(17):12098-105. PubMed ID: 1376317
[TBL] [Abstract][Full Text] [Related]
8. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
[TBL] [Abstract][Full Text] [Related]
9. Binding of plasminogen to extracellular matrix.
Knudsen BS; Silverstein RL; Leung LL; Harpel PC; Nachman RL
J Biol Chem; 1986 Aug; 261(23):10765-71. PubMed ID: 3090040
[TBL] [Abstract][Full Text] [Related]
10. Measurements of the concentration of free plasminogen activator inhibitor (PAI-1) and its complex with tissue plasminogen activator in human plasma.
Takada Y; Takada A
Thromb Res Suppl; 1988; 8():15-22. PubMed ID: 3144765
[TBL] [Abstract][Full Text] [Related]
11. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade.
Baricos WH; Cortez SL; el-Dahr SS; Schnaper HW
Kidney Int; 1995 Apr; 47(4):1039-47. PubMed ID: 7540230
[TBL] [Abstract][Full Text] [Related]
12. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
Pöllänen J; Vaheri A; Tapiovaara H; Riley E; Bertram K; Woodrow G; Stephens RW
Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2230-4. PubMed ID: 2138329
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.
Cajot JF; Bamat J; Bergonzelli GE; Kruithof EK; Medcalf RL; Testuz J; Sordat B
Proc Natl Acad Sci U S A; 1990 Sep; 87(18):6939-43. PubMed ID: 2169614
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a plasminogen activator and its inhibitor in human mesangial cells.
Lacave R; Rondeau E; Ochi S; Delarue F; Schleuning WD; Sraer JD
Kidney Int; 1989 Mar; 35(3):806-11. PubMed ID: 2496257
[TBL] [Abstract][Full Text] [Related]
15. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
[TBL] [Abstract][Full Text] [Related]
16. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.
Ehrlich HJ; Gebbink RK; Preissner KT; Keijer J; Esmon NL; Mertens K; Pannekoek H
J Cell Biol; 1991 Dec; 115(6):1773-81. PubMed ID: 1721912
[TBL] [Abstract][Full Text] [Related]
17. Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor 1 on the surface of endothelial cells.
Sakata Y; Okada M; Noro A; Matsuda M
J Biol Chem; 1988 Feb; 263(4):1960-9. PubMed ID: 3123483
[TBL] [Abstract][Full Text] [Related]
18. The activation of plasminogen by T-PA-PAI-1 complex in the absence of fibrin.
Takada Y; Takada A
Thromb Res; 1991 Jul; 63(1):169-77. PubMed ID: 1835180
[TBL] [Abstract][Full Text] [Related]
19. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
Stephens RW; Pöllänen J; Tapiovaara H; Leung KC; Sim PS; Salonen EM; Rønne E; Behrendt N; Danø K; Vaheri A
J Cell Biol; 1989 May; 108(5):1987-95. PubMed ID: 2523891
[TBL] [Abstract][Full Text] [Related]
20. The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator.
Schleef RR; Podor TJ; Dunne E; Mimuro J; Loskutoff DJ
J Cell Biol; 1990 Jan; 110(1):155-63. PubMed ID: 2104856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
